PEPGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.68 USD | -2.10% |
|
+2.55% | +71.76% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 5M | Capitalization | 378M |
|---|---|---|---|---|---|
| Net income 2024 * | -94M | Net income 2025 * | -104M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 217M | Net cash position 2025 * | 208M | EV / Sales 2025 * | 34.1 x |
| P/E ratio 2024 * |
-4.04
x | P/E ratio 2025 * |
-4.36
x | Employees | 64 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.95% |
More Fundamentals
* Assessed data
More news
Latest transcript on PepGen Inc.
More recommendations
More press releases
| 1 day | -2.10% | ||
| 1 week | +2.55% | ||
| Current month | -20.54% | ||
| 1 month | -20.54% | ||
| 3 months | +61.10% | ||
| 6 months | +114.71% | ||
| Current year | +71.76% |
1 week
10.85
12.79
1 month
10.2215.34
Current year
6.5017.51
1 year
3.7217.51
3 years
3.7220.00
5 years
3.7220.00
10 years
3.7220.00
| Managers | Title | Age | Since |
|---|---|---|---|
James McArthur
CEO | Chief Executive Officer | 62 | - |
Noel Donnelly
DFI | Director of Finance/CFO | 54 | 21-09-30 |
Isami Salcedo
PRN | Corporate Officer/Principal | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Heidi Henson
BRD | Director/Board Member | 58 | 21-06-30 |
Laurie Keating
CHM | Chairman | 70 | 22-01-18 |
| Director/Board Member | 64 | 19-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.00% | 9 M€ | +6.62% | - | |
| 0.00% | 147 M€ | +4.88% | - | |
| 0.00% | 18 M€ | +3.15% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 11.68 | -2.10% | 74,586 |
| 24-04-26 | 11.93 | +1.97% | 38,359 |
| 24-04-25 | 11.7 | -1.10% | 35,240 |
| 24-04-24 | 11.83 | +0.94% | 20,088 |
| 24-04-23 | 11.72 | +2.90% | 14,316 |
Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm EDT
More quotes
PepGen Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases. The Companyâs pipeline consists of two clinical stage programs: PGN-EDO51 for duchenne muscular dystrophy (DMD) patients who are amenable to exon 51-skipping and PGN-EDODM1 for myotonic dystrophy type 1 (DM1) patients. It also has three additional preclinical stage programs: PGN-EDO53, PGN-EDO45 and PGN-EDO44.
Calendar
2024-06-12
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
11.68
USD
Average target price
21.6
USD
Spread / Average Target
+84.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +71.76% | 378M | |
| +1.77% | 42.86B | |
| +47.70% | 41.36B | |
| +12.24% | 42.74B | |
| -8.83% | 27.68B | |
| +7.44% | 25.15B | |
| -23.01% | 18.63B | |
| +30.56% | 12.37B | |
| -1.82% | 11.92B | |
| +8.35% | 11.21B |
- Stock Market
- Equities
- PEPG Stock
